Login
$LRMR
$3.00 -$0.02 (0.66%) Live

$LRMR SEC Filings

Filed On Filing
16 Nov 2026 10-Q
16 Nov 2026 SCHEDULE 13G
16 Nov 2026 8-K: Results of Operations and Financial Condition

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

12 Nov 2026 Form 4: Hamilton Thomas Edward, Director

Bought 70,000 shares ($187K)

12 Nov 2026 Form 4: Ben-maimon Carole, Director

Bought 18,050 shares ($50K)

12 Nov 2026 Form 4: Thomas Frank E, Director

Bought 8,000 shares ($21.8K)

12 Nov 2026 Form 4: Truitt Joseph, Director

Bought 3,500 shares ($9.79K)

12 Nov 2026 Form 4: Harlow John B. Jr., President and COO

Bought 17,800 shares ($49.9K)

12 Nov 2026 Form 4: Celano Michael, Chief Financial Officer

Bought 18,460 shares ($50K)

12 Nov 2026 Form 4: Shankar Gopi, Chief Development Officer

Bought 5,000 shares ($13.5K)

09 Nov 2026 8-K: Results of Operations and Financial Condition; Other Events

pro November 2026 Larimar Therapeutics Corporate Deck Exhibit 99.2

01 Oct 2026 Form 4: Harlow John B. Jr., President and COO

Received 50,000 shares as a grant or award · Granted 800,000 Stock Option (Right to Buy)

01 Oct 2026 Form 3: Harlow John B. Jr., President and COO

No securities owned

29 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

The Board of Directors (the “Board”) of Larimar Therapeutics, Inc. (the “Company”) appointed John B. Harlow, Jr. as the Company’s President and Chief Operating Officer pursuant to the terms of an employment agreement with Mr. Harlow (the...

04 Aug 2026 10-Q
04 Aug 2026 8-K: Results of Operations and Financial Condition; Other Events

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

08 Jul 2026 Form 4: Hamilton Thomas Edward, Director

Bought 50,000 shares ($167K)

29 Jun 2026 8-K: Other Events

Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

20 May 2026 Form 4: Flynn James E, Director and 1 other

Granted 55,150 Stock Option (Right to Buy)

20 May 2026 Form 4: Leff Jonathan S, Director

Granted 55,150 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support